Tom. Thank you,
Our is efforts. growth primarily built core on strategy X
establish to U.S. indication and the in grow is first the core The market. fibromyalgia
which and neurotherapeutics growth I'll DPNCheck in may the And of program, is expanded comment activities. third market. on The the And Quell an the to now Medicare each business. these advance indications additional second addressable to lead is organic Advantage
safe nerve stimulation neuromodulation device pain unmet chronic only on The effects. need are It U.S. electrical to time, first the focused and treatment efforts the pregabalin, complex that multi-hour chronic exclusively which for chronic of [indiscernible]. proprietary milnacipran, received At respect this Novo authorization Quell duloxetine are De on in year, for relief syndromes. for It technology only and, as our pain with wearable Quell a lower FDA-approved people our of symptoms last is drugs business. treatments. commercialization additional up latter This XX our is There fibromyalgia can side have and affects First, platform. adaptive Fibromyalgia daily, is FDA-cleared and extremity pain FDA neuromodulation a indication. to Fibromyalgia the is the reduce help indicated syndrome is is critical only based our million wearable fibromyalgia. indication transcutaneous to substantial
and was small to The launch intended year of of the December. to our the and Fibromyalgia processing Quell effectiveness of quarter collect commercial the strategic phase of prescription this marketing optimize amount quarter a performance the refine This clinical of indicators. solution and key initial followed and second is to second activity in messaging
has single Our consisted commercial team our dedicated of of is headcount, which director sales. a national
to Fibromyalgia partnered national with have initial is time, a at Quell only a prescriptions basis. and the available We pharmacy this online fulfill And refills. on both cash-pay
neurologists. prescribers compared medicine the unique of pain cumulative Quell to the and prescriptions in QX, patients. RIN -- quarter XXX XXX XXX month-refills by the of in most second from specialists prescriptions XXX quarter were The are Most XX during quarter that The it There second of the number rheumatologists, first quarter. cumulative being number Fibromyalgia prescribers approximately the our been to common increased of filled in first to from XXX with in written quarter. increased have second XX% in
force process our expansion stage sales commercialization adoption. drive the on that we and This focus next to California As Texas, markets announced, on will the recently of first expect half Florida further of year. expanded decide to our the in and have we next
a the CIPN, is of or who The of receive program the for U.S. the XX% CIPN. pipeline It treatment every X and indication. Quell debilitating strategy fibromyalgia FDA-approved approximately our treatments the beyond and treatment, of to of the no cancer peripheral are many is is furthest which chronic second people The the there year. neurotherapeutics side affects as in neuropathy, chronic as chemotherapy develop along that million initial effect chemotherapy-induced element growth is
on year, time we of of severe position we to double-blinded sham-controlled at NIH-funded to the and commercialization the multicenter, be an filing FDA and support they Quell make that Depending next third for line second review in quarter XXX(k) half quarter CIPN clearance year. University which of received indication, January XXXX, in expect a FDA to treating fourth in trial and conducted decision, review initiate the completed that have enrollment moderate in CIPN a Quell should this last we now results FDA Rochester. have breakthrough the designation a study ultimate had to of based the of on the determined year. a pilot we for opportunity in believe
Moving complication for common diabetic to peripheral on based standard is conduction rapid diabetes. which only most as DPN, nerve of technology. long-term test neuropathy, is neuropathy such the neuropathy, peripheral DPNCheck test DPNCheck DPNCheck. point-of-care our peripheral or is point-of-care the gold study
to BXB DPNCheck distribution is the DPNCheck of Japan primarily market revenues of Medicare domestic U.S. through into Our business sales partners. and sales. international About and our comprised XX% from Advantage come China sales
the been several past has business growing years. for This
sector smaller into by the announced the for policy related Advantage the X We However, changes is led their substantial or Medicare to decision. among medical customers our screening a if due other months, past included At to permanent time, this uncertainty know DPNCheck was in uncertainty customer Medicare which Medicaid several this programs, Services. Centers temporary largest not Advantage this other we and tests. suspending and factors and injected Medicare believe do
putting These on Medicare early direction Advantage too magnitude material are it's revenues, to and the downward although pressure of determine DPNCheck impact. changes the
will of expect flow However, operating we line the margins. that by continue generate virtue positive to attractive its cash DPNCheck business
there is get we for a We uncertainty. this also once of period through believe resumed growth potential
we'd this and comments, point. prepared happy questions be our represents that to And take at
